These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37745208)

  • 21. Age- and breed-matched retrospective cohort study of malignancies and benign skin masses in 660 dogs with allergic dermatitis treated long-term with versus without oclacitinib.
    Lancellotti BA; Angus JC; Edginton HD; Rosenkrantz WS
    J Am Vet Med Assoc; 2020 Sep; 257(5):507-516. PubMed ID: 32808904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a questionnaire to assess owner and canine quality-of-life and treatment satisfaction in canine allergic dermatitis.
    Wells JR; Hillier A; Holland R; Mwacalimba K; Noli C; Panter C; Tatlock S; Wright A
    Vet Dermatol; 2024 Aug; 35(4):386-399. PubMed ID: 38361109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics.
    Gonzales AJ; Fleck TJ; Humphrey WR; Galvan BA; Aleo MM; Mahabir SP; Tena JK; Greenwood KG; McCall RB
    Vet Dermatol; 2016 Feb; 27(1):34-e10. PubMed ID: 26666963
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.
    Denti D; Caldin M; Ventura L; De Lucia M
    Vet Dermatol; 2022 Apr; 33(2):149-e42. PubMed ID: 35014745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
    De Caro Martins G; da Costa-Val AP; Coura FM; Diamantino GML; Nogueira MM; de Oliveira Melo-Junior OA; Giunchetti RC; da Silveira-Lemos D; Melo MM
    Vet Dermatol; 2022 Apr; 33(2):142-e40. PubMed ID: 34747068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of Cytopoint in the Allergic Dog.
    Gober M; Hillier A; Vasquez-Hidalgo MA; Amodie D; Mellencamp MA
    Front Vet Sci; 2022; 9():909776. PubMed ID: 35928119
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concurrent short-term use of prednisolone with cyclosporine A accelerates pruritus reduction and improvement in clinical scoring in dogs with atopic dermatitis.
    Dip R; Carmichael J; Letellier I; Strehlau G; Roberts E; Bensignor E; Rosenkrantz W
    BMC Vet Res; 2013 Sep; 9():173. PubMed ID: 24004561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acceptance of oclacitinib maleate (Apoquel®) chewable tablets in client-owned dogs with allergic and atopic dermatitis.
    Visser M; Walsh K; King V; Sture G; Caneva L
    BMC Vet Res; 2022 Mar; 18(1):103. PubMed ID: 35300697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dog Owners' Perceptions of the Convenience and Value of Chewable Oclacitinib: Quantitative Survey Data from an International Survey.
    Wright A; Hillier A; Lambert J; Mwacalimba K; Lloyd N; Kagiwada T; Hashiguchi Y; Hours C; Riley D; Enstone A; Wyn R
    Animals (Basel); 2024 Mar; 14(6):. PubMed ID: 38540050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
    Carrasco I; Ferrer L; Puigdemont A
    J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of oclacitinib as antipruritic drug during sarcoptic mange infestation treatment.
    Cornegliani L; Guidi E; Vercelli A
    Vet Dermatol; 2020 Dec; 31(6):505. PubMed ID: 33226173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Demonstration of rebound phenomenon following abrupt withdrawal of the JAK1 inhibitor oclacitinib.
    Fukuyama T; Ganchingco JR; Bäumer W
    Eur J Pharmacol; 2017 Jan; 794():20-26. PubMed ID: 27847179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of topical oclacitinib and nail trimming as a treatment for murine ulcerative dermatitis in laboratory mice.
    Davison SE; Emmer KM; Ugiliweneza B; Sherwood LC
    PLoS One; 2022; 17(10):e0276333. PubMed ID: 36256616
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of serum macrophage migration inhibitory factor (MIF) and correlation with severity and pruritus scores in client owned dogs with atopic dermatitis.
    Gow DJ; Jackson H; Forsythe P; Gow AG; Mellanby RJ; Hume DA; Nuttall T
    Vet Dermatol; 2019 Jan; ():. PubMed ID: 30672038
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measurement of serum Interleukin 34 (IL-34) and correlation with severity and pruritus scores in client-owned dogs with atopic dermatitis.
    Gow DJ; Jackson H; Forsythe P; Nuttall T; Gow AG; Mellanby RJ; Hume DA
    Vet Dermatol; 2020 Oct; 31(5):359-e94. PubMed ID: 32794277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A masked, randomised clinical trial evaluating the efficacy and safety of lokivetmab compared to saline control in client-owned dogs with allergic dermatitis.
    Van Brussel L; Moyaert H; Escalada M; Mahabir SP; Stegemann MR
    Vet Dermatol; 2021 Oct; 32(5):477-e131. PubMed ID: 34180084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and tolerance of a novel topical TRPV-1 channel antagonist in dogs with allergic pododermatitis.
    Serra Fabregat X; de Pablo MÁ; Hernán-Pérez C; Diéguez E; Valero Coppin O; Genové Corominas E
    Vet Dermatol; 2023 Dec; 34(6):514-522. PubMed ID: 37309264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A blinded, randomized, placebo-controlled, dose determination trial of lokivetmab (ZTS-00103289), a caninized, anti-canine IL-31 monoclonal antibody in client owned dogs with atopic dermatitis.
    Michels GM; Ramsey DS; Walsh KF; Martinon OM; Mahabir SP; Hoevers JD; Walters RR; Dunham SA
    Vet Dermatol; 2016 Dec; 27(6):478-e129. PubMed ID: 27647569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
    Qin JJ; Zhu H; Song ZW; Hou XJ; Wang XM; Wang L; Li JX
    Res Vet Sci; 2024 May; 171():105221. PubMed ID: 38490043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of Antimicrobial Treatment in Dogs with Atopic Dermatitis: An Observational Study.
    Sofou EI; Aleksandrova S; Badulescu E; Chatzis M; Saridomichelakis M
    Vet Sci; 2022 Jul; 9(8):. PubMed ID: 35893778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.